379 related articles for article (PubMed ID: 28915889)
1. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
2. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
3. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis.
Aono Y; Kishi M; Yokota Y; Azuma M; Kinoshita K; Takezaki A; Sato S; Kawano H; Kishi J; Goto H; Uehara H; Izumi K; Nishioka Y
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):793-801. PubMed ID: 24885373
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.
Inomata M; Kamio K; Azuma A; Matsuda K; Kokuho N; Miura Y; Hayashi H; Nei T; Fujita K; Saito Y; Gemma A
Respir Res; 2014 Feb; 15(1):16. PubMed ID: 24507087
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
7. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.
Kishi M; Aono Y; Sato S; Koyama K; Azuma M; Abe S; Kawano H; Kishi J; Toyoda Y; Okazaki H; Ogawa H; Uehara H; Nishioka Y
PLoS One; 2018; 13(12):e0209786. PubMed ID: 30596712
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
[TBL] [Abstract][Full Text] [Related]
10. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-α-induced pulmonary fibrosis.
Madala SK; Edukulla R; Schmidt S; Davidson C; Ikegami M; Hardie WD
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):777-86. PubMed ID: 24199692
[TBL] [Abstract][Full Text] [Related]
12. Imatinib ameliorates bronchiolitis obliterans via inhibition of fibrocyte migration and differentiation.
Watanabe S; Kasahara K; Waseda Y; Takato H; Nishikawa S; Yoneda T; Hara J; Sone T; Abo M; Kimura H; Nakao S
J Heart Lung Transplant; 2017 Feb; 36(2):138-147. PubMed ID: 27388852
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects.
Abe S; Sato S; Aono Y; Azuma M; Kishi M; Koyama K; Takahashi N; Kagawa K; Kawano H; Nishioka Y
J Med Invest; 2020; 67(1.2):102-112. PubMed ID: 32378592
[TBL] [Abstract][Full Text] [Related]
16. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis.
Mehrad B; Burdick MD; Strieter RM
Int J Biochem Cell Biol; 2009; 41(8-9):1708-18. PubMed ID: 19433312
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
18. Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis.
Morizumi S; Sato S; Koyama K; Okazaki H; Chen Y; Goto H; Kagawa K; Ogawa H; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Am J Respir Cell Mol Biol; 2020 Sep; 63(3):317-326. PubMed ID: 32338990
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.
Lin T; Gong L
Drug Des Devel Ther; 2017; 11():1147-1158. PubMed ID: 28435226
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
